secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2024-12-26T23:59:59+00:00
Accession:  0000950103-24-018350
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen sells FCX-007 assets for $8.5M cash, exits Castle Creek collaboration
------------------------------------------------------------------------------

- Asset Acquisition Agreement with Innovator 21 (Paragon affiliate) closed Dec 24, 2024 for $8.5M cash.
- Sold IP and royalty rights related to FCX-007, a clinical-stage candidate for Epidermolysis Bullosa.
- Precigen has no further rights or obligations to Castle Creek or retained product royalties.
- Proceeds to be used for working capital and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324018350/0000950103-24-018350-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324018350/dp222589_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-24-018350

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer